[Hormone replacement therapy in peri- and postmenopause. Routine use is not indicated].
Hormone replacement therapy (HRT) with estrogens (in non-hysterectomized women with estrogens and progestins) during the peri- and postmenopausal period has been widely applied for many years. On the basis of new data, HRT is currently being critically reviewed. HRT administered for up to 5 years to treat climacteric hot flashes, mood changes and sleep disturbances continues to be advocated and is largely safe. When HRT is used for longer periods, as required for the prevention of osteoporosis, a possible increase in the relative risk for breast cancer must be considered. Correctly applied in combination with an adequate dose of progestins, HRT can avoid an increase in the endometrial cancer risk. HRT is no longer recommended for secondary prevention of cardiovascular disease, and its use in primary prevention has not been convincingly demonstrated. The hoped-for efficacy of HRT in the prevention of Alzheimer's disease has not been confirmed by the data. Selective estrogen receptor modulators (e.g. Raloxifene) and biphosphonates are efficacious drugs for the prevention and treatment of osteoporosis. For women at risk of developing cardiovascular disease, changes in lifestyle, lipid-lowering drugs (statins), blood pressure control, use of acetylsalicylic acid, among others, have well-documented efficacy in primary and secondary prevention.
Emons
G
G
Klinik für Gynäkologie und Geburtshilfe, Georg-August-Universität Göttingen. emons@med.uni-goettingen.de
Westphalen
S
S
D000544:Alzheimer Disease / Q000517:prevention & control; D001943:Breast Neoplasms / Q000139:chemically induced; D002318:Cardiovascular Diseases / Q000517:prevention & control; D002986:Clinical Trials as Topic; D016889:Endometrial Neoplasms / Q000517:prevention & control; D015914:Estrogen Replacement Therapy; D005260:Female; D020249:Hormone Replacement Therapy / Q000009:adverse effects; D006801:Humans; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control; D010051:Ovarian Neoplasms / Q000139:chemically induced; D011322:Primary Prevention; D011372:Progestins / Q000008:administration & dosage; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use; D012307:Risk Factors; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use; D013927:Thrombosis / Q000139:chemically induced; D013997:Time Factors
D011372:Progestins; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride
Hormonersatztherapie in der Peri- und Postmenopause. Ein routinemässiger Einsatz ist nicht indiziert.